✦ LIBER ✦

C2 monitoring of cyclosporine in de novo liver transplant recipients: The clinician's perspective

✍ Scribed by Federico Villamil; Stephen Pollard

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 197 KB
Volume: 10
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.20112

No coin nor oath required. For personal study only.

✦ Synopsis

Abbreviations: AUC 0 -6 , area under the curve for the first six hours post-dose; AUC 0 -12 , area under the curve for the first twelve hours post-dose; C 0, trough blood concentration; C 2, blood concentration at 2 hours after dose; C 4 , blood concentration at 4 hours after dose; C 6 , blood concentration at 6 hours after dose; CsA, cyclosporine; ME, microemulsion; MMF, mycophenolate mofetil.

📜 SIMILAR VOLUMES

12-month follow-up analysis of a multice

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

✍ Gary Levy; Gian Luca Grazi; Fernando Sanjuan; Youmin Wu; Ferdinand Mühlbacher; D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

For complete listing of investigators and centers, see

Increased incidence of early de novo can

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age

✍ Angela S. W. Tjon; Jerome Sint Nicolaas; Jaap Kwekkeboom; Robert A. de Man; Geer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 1 views

The goal of this study was to determine the risk factors for de novo cancer after liver transplantation (LTx). Retrospective analyses were performed in 385 LTx patients who underwent transplantation between 1986 and 2007. In total, 50 (13.0%) recipients developed de novo malignancy. The cumulative i

A randomized, prospective, pharmacoecono

A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients

✍ Surendra Shenoy; Karen L. Hardinger; Jeffrey Crippin; Kevin Korenblat; Mauricio 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 1 views

Two-hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)-based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of

The immunological monitoring of alloreac

The immunological monitoring of alloreactive responses in liver transplant recipients: A review

✍ Raymond Reding; Jérémie Gras; Dinh Quang Truong; Grégoire Wieërs; Dominique Lati 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

The aim of this work is to review the current knowledge in the field of immunological monitoring of allogenic responsiveness in clinical liver transplantation. When compared to other solid-organ transplants, liver allografts are considered as immunologically privileged, and, accordingly, constitute

Improved cyclosporine bioavailability in

Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation

✍ Cooney, Gerard F. ;Dunn, Stephen P. ;Sommerauer, John ;Lindsay, Christine ;McDia 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 124 KB

Black transplant recipients are associated with low cyclosporine bioavailability, which may contribute to the poorer clinical outcomes observed with these patients. In this analysis, we compared cyclosporine exposure in black (n ‫؍‬ 9) and nonblack (n ‫؍‬ 18) pediatric maintenance liver transplant r

Safety, tolerability, and efficacy of ev

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou